Sign In
Buy OKYO
$1.55
+0.0700 (+4.73%)
At Close: Jul 24, 2026
OKYO Pharma appoints leading ophthalmologists to its Scientific Advisory Board
09:23am, Wednesday, 31'st Jan 2024
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has appointed three prominent ophthalmologists and corneal surgeons to its Scientific Advisory Board to advise management on the development of its ther
OKYO Pharma reports 'statistical significance' achieved in Phase 2 trial of OK-101 in dry eye disease
09:56am, Monday, 08'th Jan 2024
OKYO Pharma Ltd (NASDAQ:OKYO) has announced positive safety and efficacy results in its Phase 2 trial of OK-101 ophthalmic solution for the treatment of inflammatory dry eye disease (DED). The trial,
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
09:30am, Friday, 05'th Jan 2024
LONDON and NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory
OKYO Pharma on track as last patient enrolled in trial to treat dry eye disease completes final protocol visit
08:17am, Monday, 04'th Dec 2023
OKYO Pharma Ltd (NASDAQ:OKYO) told investors that it is on track to release top-line results from its phase 2 clinical trial of OK-101 to treat dry eye disease (DED) this month after the last patient
OKYO Pharma files IND application OK-101 to treat Neuropathic Corneal Pain
08:20am, Monday, 09'th Oct 2023
OKYO Pharma Ltd (NASDAQ:OKYO), the clinical-stage drug developer noted, told investors it has filed an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for th
LONDON and NEW YORK, Oct. 09, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory
OKYO Pharma phase II dry eye trial making encouraging progress
07:58am, Thursday, 05'th Oct 2023
OKYO Pharma Ltd (NASDAQ:OKYO), the clinical-stage drug developer, has reported encouraging safety data for its ongoing phase II clinical trial of OK-101, a drug candidate aimed at treating dry eye dis
